Drug Topics August 4, 2024
As clinical research continues, investigators are learning more about how GLP-1 drugs modify cardiovascular risks.
Ambarish Pandey, MD, associate professor of cardiology in internal medicine at the University of Texas Southwestern Medical Center in Dallas, Texas, sat down with Drug Topics ahead of the American Society for Preventive Cardiology Congress on CVD Prevention to discuss recent advancements in the understanding of glucagon-like peptide-1 (GLP-1) therapies’ mechanism of action, clinical guidelines for GLP-1 use, and more.
Drug Topics: What advancements in the understanding of GLP-1 receptor agonists’ mechanisms of action have influenced their use in the management of diabetes and obesity?
Ambarish Pandey, MD: The way these drugs work is by…suppressing appetite and inducing early satiety, which reduces overall caloric intake....
Today's Sponsors
Today's Sponsor